Published in Br J Dermatol on February 01, 2007
Immune Signature of Palmoplantar Pustulosis (PPP) | NCT01780857
Treatment recommendations for psoriatic arthritis. Ann Rheum Dis (2008) 1.85
Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol (2008) 1.08
Psoriasis and other complex trait dermatoses: from Loci to functional pathways. J Invest Dermatol (2011) 1.07
Abnormal aquaporin-3 protein expression in hyperproliferative skin disorders. Arch Dermatol Res (2011) 0.94
Serum levels of LL-37 and inflammatory cytokines in plaque and guttate psoriasis. Mediators Inflamm (2014) 0.88
Psoriasis. Cold Spring Harb Perspect Med (2014) 0.85
Spectrum of non-infectious erythematous, papular and squamous lesions of the skin. Indian J Dermatol (2010) 0.84
Two case reports of generalized pustular psoriasis of pregnancy: Different outcomes. Obstet Med (2016) 0.79
Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire. Health Qual Life Outcomes (2012) 0.78
Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol (2016) 0.77
Cutaneous microdialysis: cytokine evidence for altered innate reactivity in the skin of psoriasis patients? AAPS J (2012) 0.77
Update of the management of chronic psoriasis: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol (2010) 0.76
Antimicrobial peptide LL-37 along with peptidoglycan drive monocyte polarization toward CD14(high)CD16(+) subset and may play a crucial role in the pathogenesis of psoriasis guttata. Am J Transl Res (2015) 0.75
Candidate gene polymorphisms and risk of psoriasis: A pilot study. Exp Ther Med (2016) 0.75
Association of C-Reactive Protein (rs1205) Gene Polymorphism with Susceptibility to Psoriasis in South Indian Tamils. J Clin Diagn Res (2016) 0.75
Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J (2016) 0.75
Gene Expression Analysis of Inflammatory Cytokines in Korean Psoriatic Patients. Ann Dermatol (2017) 0.75
Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis. Eur J Clin Pharmacol (2017) 0.75
Bone marrow cells regenerate infarcted myocardium. Nature (2001) 21.24
A peptide antibiotic from human skin. Nature (1997) 7.64
Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A (2001) 7.19
Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic. J Biol Chem (2000) 6.19
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med (2001) 5.67
Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. J Immunol (1987) 4.43
British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol (2009) 4.12
Disease concomitance in psoriasis. J Am Acad Dermatol (1995) 3.92
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol (2001) 3.92
The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N Engl J Med (1977) 3.61
European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol (2009) 3.56
Tissue antibodies in dermatitis herpetiformis and adult coeliac disease. Lancet (1971) 3.50
Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med (1992) 3.20
Small-intestinal structure and function and haematological changes in dermatitis herpetiformis. Lancet (1967) 3.11
British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol (2005) 3.10
Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol (1984) 2.93
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol (2007) 2.85
Circulating immune complexes in dermatitis herpetiformis. Lancet (1973) 2.78
Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol (1985) 2.74
Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis (2005) 2.61
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest (1999) 2.58
T-cell subpopulations in the blood and skin of patients with psoriasis. Br J Dermatol (1984) 2.54
Anti-reticulin antibodies in childhood coeliac disease. Lancet (1971) 2.54
Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet (1997) 2.48
Psoriasis assessment tools in clinical trials. Ann Rheum Dis (2005) 2.24
Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem (1990) 2.23
Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann N Y Acad Sci (2001) 2.17
Antireticulin antibody: incidence and diagnostic significance. Gut (1973) 2.15
Lymphocytic infiltration of epithelium in diagnosis of gluten-sensitive enteropathy. Br Med J (1972) 2.11
Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am Rev Respir Dis (1992) 2.11
Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet (2001) 2.11
Treatment of mild to moderate seborrhoeic dermatitis with MAS064D (Sebclair), a novel topical medical device: results of a pilot, randomized, double-blind, controlled trial. J Eur Acad Dermatol Venereol (2008) 2.11
Structure determination of a human lymphocyte derived neutrophil activating peptide (LYNAP). Biochem Biophys Res Commun (1988) 2.10
Effect of gluten-free diet on dermatological, intestinal, and haematological manifestations of dermatitis herpetiformis. Lancet (1968) 2.09
Linkage analysis of human leukocyte antigen (HLA) markers in familial psoriasis: strong disequilibrium effects provide evidence for a major determinant in the HLA-B/-C region. Am J Hum Genet (1998) 2.09
Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today (1995) 2.09
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis (2005) 2.08
Concordance between telepathologic diagnosis and conventional histopathologic diagnosis: a multiobserver store-and-forward study on 20 skin specimens. Arch Dermatol (2002) 2.07
A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. Br J Dermatol (2010) 2.04
Secretion of novel and homologous neutrophil-activating peptides by LPS-stimulated human endothelial cells. J Immunol (1989) 2.04
Clearance of skin lesions in dermatitis herpetiformis after gluten withdrawal. Lancet (1973) 2.01
Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science (1994) 1.99
Absence of toxicity of oats in patients with dermatitis herpetiformis. N Engl J Med (1997) 1.98
Cutaneous T-cell lymphoma in association with silicone breast implants. J Am Acad Dermatol (1995) 1.96
Identification of C5ades arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. J Invest Dermatol (1986) 1.96
IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes (2001) 1.92
Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet (2000) 1.86
The genetics of psoriasis. Arch Dermatol (1994) 1.84
Structural aspects of initial psoriatic lesions. Arch Dermatol Forsch (1974) 1.81
Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol (2007) 1.80
Localization of neutrophil-activating peptide-1/interleukin-8-immunoreactivity in normal and psoriatic skin. J Invest Dermatol (1991) 1.79
Mutations in cornea-specific keratin K3 or K12 genes cause Meesmann's corneal dystrophy. Nat Genet (1997) 1.75
Clearance of psoriasis with low dose cyclosporin. Br Med J (Clin Res Ed) (1986) 1.75
Comparative study of 5% permethrin cream and 1% lindane lotion for the treatment of scabies. Arch Dermatol (1990) 1.72
In vitro and in vivo anti-melanoma effects of ciglitazone. J Invest Dermatol (2009) 1.67
Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol (1998) 1.67
Dermatitis herpetiformis: an evaluation of diagnostic criteria. Br J Dermatol (1974) 1.66
Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol (1989) 1.65
Dose-effects of 8-methoxypsoralen and UVA in cultured human lymphocytes. Br J Dermatol (1978) 1.64
A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol (2010) 1.61
Gluten-free diet and reintroduction of gluten in dermatitis herpetiformis. Arch Dermatol (1969) 1.60
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol (2013) 1.60
Clinical reactogenicity of intradermal bacille Calmette-Guérin vaccination. Clin Infect Dis (1999) 1.59
Variants in the 5q31 cytokine gene cluster are associated with psoriasis. Genes Immun (2007) 1.59
Psoriasis and streptococci: the natural selection of psoriasis revisited. Br J Dermatol (2009) 1.58
Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years. Allergy (2006) 1.57
Expression of interferon-gamma receptors in normal and psoriatic skin. J Invest Dermatol (1992) 1.57
Binding of wheat gliadin in vitro to reticulum in normal and dermatitis herpetiformis skin. J Invest Dermatol (1981) 1.57
Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol (2003) 1.56
Long term follow-up of dermatitis herpetiformis with and without dietary gluten withdrawal. Br J Dermatol (1982) 1.56
Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis (2005) 1.56
Characterization of skin-infiltrating lymphocytes in patients with psoriasis. J Invest Dermatol (1991) 1.55
The small intestine in dermatitis herpetiformis. J Clin Pathol (1974) 1.54
Immunoglobulins in the skin in dermatitis herpetiformis and coeliac disease. Lancet (1972) 1.53
The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br J Dermatol (1987) 1.53
The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol (2002) 1.52
Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study. Br J Dermatol (2009) 1.51
The annual cost of psoriasis. J Am Acad Dermatol (1993) 1.51
The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum. J Dermatolog Treat (2001) 1.50
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol (2013) 1.50
Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. A word of caution in light of the expanding use of this 'steroid-sparing' agent. Arch Intern Med (1990) 1.50
Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol (2009) 1.50
IL-1 alpha or tumor necrosis factor-alpha stimulate release of three NAP-1/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts. J Immunol (1990) 1.50
Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. Br J Dermatol (2005) 1.49
[Stimulation of epidermal DNA syntgesis through vitamin A acid]. Arch Klin Exp Dermatol (1968) 1.48
Site of action of cortisol in cellular immunity. J Immunol (1973) 1.46
Differential expression of Ia by murine keratinocytes and gut epithelium in response to recombinant gamma-interferon. J Invest Dermatol (1989) 1.46
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol (2012) 1.46
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol (1996) 1.45
Multiple immune complexes and hypocomplementaemia in dermatitis herpetiformis and coeliac disease. Lancet (1976) 1.45
Increased incidence of malignancy in dermatitis herpetiformis. Br Med J (Clin Res Ed) (1983) 1.45
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol (2012) 1.45
Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol (2007) 1.44